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A B S T R A C T
Intravesical drug administration is used to deliver cytotoxic agents through a catheter to treat bladder
cancer. One major limitation of this approach is poor retention of the drug in the bladder due to periodic
urine voiding. Mucoadhesive dosage forms thus offer signiﬁcant potential to improve drug retention in
the bladder. Here, we investigate thiolated silica nanoparticles retention on porcine bladder mucosa in
vitro, quantiﬁed through Wash Out50 (WO50) values, deﬁned as the volume of liquid necessary to remove
50% of the adhered particles from a mucosal tissue. Following irrigation with artiﬁcial urine solution, the
thiolated nanoparticles demonstrate signiﬁcantly greater retention (WO50 up to 36 mL) compared to
non-mucoadhesive dextran (WO50 7 mL), but have weaker mucoadhesive properties than chitosan
(WO50 89 mL). PEGylation of thiolated silica reduces their mucoadhesion with WO50 values of 29 and
8 mL for particles decorated with 750 and 5000 Da PEG, respectively. The retention of thiolated silica
nanoparticles is dependent on their thiol group contents and physical dimensions.
ã 2016 Elsevier B.V. All rights reserved.
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Urinary bladder cancer and interstitial cystitis are widespread
and serious urological conditions; bladder cancer is the ninth most
common cancer in the world, with approximately 430,000 new
patients diagnosed with this condition in 2012 (WCRF, 2015).
Intravesical drug delivery administers therapeutic agents directly
into the urinary bladder via a catheter (Malmstrom, 2003; Gasion
and Cruz, 2006; Nirmal et al., 2012; Haupt et al., 2013). This
provides localized treatment, minimizes systemic side effects and
allows direct exposure of the affected tissue to therapeutic agents.
However, intravesical drug delivery also has some limitations. The
normal capacity of the bladder is 400–600 mL, but ﬁlling to
150–300 mL causes the urge to urinate. Due to periodical voiding of
urine from the bladder, instilled drug formulations can be rapidly
washed out, requiring frequent repeated administration (Guha-
sarkar and Banerjee, 2010). Additionally, frequent use of catheters
is inconvenient for the patients and may cause inﬂammatory
reactions and infections.
The residence time of a dosage form in the bladder can
potentially be improved by using mucoadhesive materials, which
could adhere to the epithelial mucosa and resist drug washout.* Corresponding author.
E-mail address: v.khutoryanskiy@reading.ac.uk (V.V. Khutoryanskiy).
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0378-5173/ã 2016 Elsevier B.V. All rights reserved.Mucoadhesive formulations for intravesical drug delivery must
satisfy three main criteria: they should adhere rapidly to the
bladder mucosa, should not interfere with the normal functions of
the bladder and should be retained in situ even after urination
(Tyagi et al., 2006).
Hydrophilic polymers are traditionally used as mucoadhesive
materials in many formulations for transmucosal drug delivery
(Peppas and Sahlin, 1996; Andrews et al., 2009; Khutoryanskiy,
2011) and commonly used are chitosan and carbomers (weakly
cross-linked poly(acrylic acid)). The adhesion of these polymers to
mucosal surfaces is through non-covalent interactions such as
hydrogen bonding, electrostatic attraction, hydrophobic effects
and diffusion and interpenetration (Khutoryanskiy, 2011). Recent-
ly, a number of chemical approaches have been reported to
enhance mucoadhesive properties of polymers including the
introduction of thiol groups (Bernkop-Schnurch, 2005), acrylate
groups (Davidovich-Pinhas, 2011), catechols (Kim et al., 2015) and
boronates (Liu et al., 2015).
The literature contains few reports on chemically modiﬁed and
enhanced mucoadhesive materials for intravesical drug delivery.
Barthelmes et al. (2011, 2013) used thiolated particles based on
chitosan and demonstrated that retention in rat bladder in vivo was
approximately 170-fold greater than for a small-molecular weight
ﬂuorescent marker. Storha et al. (2013) developed thiolated
nanoparticles using thiol-ene click chemistry and studied their
retention on porcine urinary bladder mucosa in vitro. Zhang et al.
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modiﬁed mesoporous silica nanoparticles with hydroxyl, amino,
and thiol groups. They demonstrated that retention of thiol-
functionalized nanoparticles on the urothelium was signiﬁcantly
higher than the hydroxyl- and amino-functionalized materials.
Previously we have reported the synthesis of thiolated silica
nanoparticles using self-condensation of (3-mercaptopropyl)tri-
methoxysilane in dimethylsulfoxide (Irmukhametova et al., 2011;
Irmukhametova et al., 2012; Mun et al., 2014a). These nano-
particles exhibited strong adhesion to ocular tissues and withstood
repetitive washes with artiﬁcial tear ﬂuid (Irmukhametova et al.,
2011; Mun et al., 2014b). Here, we evaluate the retention of
thiolated and PEGylated silica nanoparticles on porcine urinary
bladder in vitro and show the effects of nanoparticle size on their
mucoadhesive properties. Retention of the nanoparticles depends
on both their thiol content and dimensions. Further, we introduce a
novel quantitative method to compare the retention efﬁciency of
liquid formulations on mucosal tissues through the use of Wash
Out50 (WO50) values, deﬁned as the volume of a biological ﬂuid
required to wash out 50% of a mucoadhesive formulation from a
substrate.
2. Materials and methods
2.1. General materials
(3-Mercaptopropyl)-trimethoxysilane (MPTS), dimethyl sulfox-
ide, dimethyl formamide, acetonitrile, L-cysteine hydrochloride,
5,50-dithiobis(2-nitrobenzoic acid), 5-(iodoacetamido)-ﬂuoresce-
in, methoxypolyethylene glycol 750 Da maleimide, methoxypoly-
ethylene glycol 5000 Da maleimide, urea, chitosan (103 kDa),
ﬂuorescein isothiocyanate (FITC) and ﬂuorescein isothiocyanate
dextran (FITC-dextran) were purchased from Sigma-Aldrich
(Gillingham, UK). Methanol was purchased from Fisher Scientiﬁc
Ltd (UK) and used as received.
2.2. Synthesis of thiolated silica nanoparticles
Thiolated nanoparticles were synthesized according to our
previously published protocol (Mun et al., 2014b). Brieﬂy, 0.75 mL
(0.2 mol/L) or 0.38 mL (0.1 mol/L) of MPTS was mixed with 20 mL of
DMSO and 0.5 mL of 0.5 mol/L NaOH aqueous solution. Addition-
ally, the same procedure was repeated with 0.38 mL of MPTS in
20 mL of dimethylformamide (DMF) and acetonitrile. The reaction
was conducted with air bubbling and allowed to proceed for 24 h
under constant stirring at room temperature. Nanoparticles were
puriﬁed by dialysis against deionized water (5L, 8 changes of
water) using 12–14 kDa molecular weight cut off dialysis tubing
(Medicell International Ltd, UK).
2.3. Ellman’s assay
Thiol-group content of the nanoparticles was determined by
Ellman’s assay. 0.2-0.3 mg of freeze-dried nanoparticles were
hydrated in 500 mL of phosphate buffer solution (0.5 mol/L, pH 8)
and allowed to react with 500 mL of 5,50-dithio-bis-(2-nitrobenzoic
acid) (DTNB) for 2 h. Absorbance was then measured at 420 nm
(Epoch Microplate Spectrophotometer, BioTek Instruments, USA).
The calibration curve was constructed with cysteine hydrochloride
solutions over the concentration range of 25–175 mmol/L
(R2 = 0.9998).
2.4. Synthesis of ﬂuorescently-labelled thiolated silica nanoparticles
Thiolated silica nanoparticles were labelled with 5-(iodoace-
tamido)-ﬂuorescein (5-IAF) by adding 3, 0.3, 0.4 and 0.05 mg of5-IAF to 18, 20, 10 and 10 mL aqueous dispersions of thiolated
nanoparticles, respectively. The amount of 5-IAF added was
calculated with regard to molar ratios such that 5 mmol of
ﬂuorophore was added to 50 mmol of SH-groups of thiolated
nanoparticles. The reaction mixture was stirred for 16 h at room
temperature protected from light. Fluorescently-labelled nano-
particles were then puriﬁed by dialysis against deionized water in
the dark, according to the above protocol.
2.5. PEGylation of ﬂuorescently-labelled silica nanoparticles
5 mL aqueous dispersions of ﬂuorescently-labelled nanopar-
ticles were mixed with 100 mg of methoxypolyethylene glycol
maleimide of two molecular weights (750 or 5000 Da). The
reaction mixture was stirred during 16 h at room temperature
protected from light, resulting in the formation of PEGylated silica
nanoparticles. PEGylated nanoparticles were puriﬁed by dialysis in
the dark as above.
2.6. Synthesis of ﬂuorescently-labelled chitosan
FITC-chitosan, used as a positive control for mucoadhesion
tests, was synthesized according to our previously published
protocol (Cook and Tzortzis, 2011). 1% w/v chitosan solution was
prepared in 100 mL of 0.1 mol/L acetic acid, followed by the
addition of 100 mL of dehydrated methanol and 50 mL of 2 mg/mL
FITC solution in methanol. The reaction was allowed to proceed for
3 h in the dark at room temperature and then precipitated in 1 L of
0.1 M NaOH. The precipitate was ﬁltered and dialyzed against 4 L of
deionized water in the dark. The resulting product was freeze-
dried (Heto Power Dry LL 3000 freeze-drier, Thermo Electron
Corporation) and kept wrapped in aluminum foil to avoid exposure
to light. For experiments, 0.05% solutions of FITC-chitosan in 0.1 M
acetic acid were used.
2.7. Preparation of ﬂuorescein isothiocyanate dextran (4000 Da)
(FITC-dextran) solution
FITC-dextran solution, used as a negative control in mucoad-
hesion studies, was prepared by dissolving 2 mg of FITC-dextran
(4000 Da) in 10 mL of deionized water and was left for 5 h under
permanent stirring at room temperature.
2.8. Dynamic light scattering (DLS)
The size of ﬂuorescently-labelled silica nanoparticles and their
polydispersity (PDI) values were determined by dynamic light
scattering using a Nano-ZS series (Malvern Instruments, UK) at
25 C. Each sample was analyzed three times from which the
mean  standard deviation hydrodynamic diameter values were
calculated.
2.9. Fluorescence spectroscopy
Fluorescence spectra were recorded for ﬂuorescently-labelled
thiolated and PEGylated nanoparticles using a FP-6200 Spectro-
ﬂuorometer (Jasco, UK) over the wavelength range 505–700 nm
(lex = 492 nm).
2.10. Preparation of artiﬁcial urine solution
Artiﬁcial urine was prepared according to a previously
published protocol with slight modiﬁcations (Chutipongtanate
and Thongboonkerd, 2010). The following compounds were
dissolved in deionized water by stirring for 3 h at room
temperature, before making the total volume to 2 L: urea
Fig. 1. Size distribution of thiolated silica nanoparticles, ﬂuorescently-labelled with
5-IAF.
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MgSO47H2O (1.00 g), NaHCO3 (0.34 g), Na2SO4 (0.26 g), NaH2-
PO4H2O (1.00 g), and Na2HPO4 (0.11 g). The pH of the resulting
solution was 6.2, which is in agreement with Chutipongtanate and
Thongboonkerd (2010). The artiﬁcial urine solution was kept at
37 C throughout the experiments.
2.11. Mucoadhesion studies using porcine urinary bladder
Mucoadhesive studies used a ﬂuorescence microscope (Zeiss
Imager A1) with an AxioCam MRm Zeiss camera at 5  magniﬁca-
tion with 11.4 ms exposure time and 1388  1040 pixels. The
porcine urinary bladders used in these experiments were obtained
from P.C. Turner Abattoir (Hampshire, UK). Freshly-extracted
urinary bladders were transported to the laboratory in a cold box
and stored in the fridge at 4 C overnight prior to retention studies.
A sample of the bladder tissue (approximately 2  3 cm) was
carefully excised, avoiding contact with the mucosal side of the
tissue, and was brieﬂy rinsed with 3 mL of artiﬁcial urine
solution. Experiments were performed with the bladder tissue
maintained at 37 C in a water bath. Background microscopy
images were recorded for each tissue sample prior to dosing with
200 mL of either ﬂuorescently-labelled nanoparticle dispersion or
polymers (controls). Once the test material was placed onto the
mucosal surface, ﬂuorescence microscopy images were again
taken, followed by 7 washing cycles, for each of which the bladder
tissue was irrigated with 10 mL of artiﬁcial urine solution at
5 mL/min using a syringe pump. Fluorescence microscopy images
(3 for each sample) were recorded initially after treatment and
after each wash with the bladder tissue being placed onto a 75 mm
x 25 mm glass slide. Each experiment was conducted in triplicate.
Microscopy images were analysed with Image J software, the mean
ﬂuorescence values (ﬂuorescence, a.u.) after each wash were
calculated and a histogram of ﬂuorescence intensity distribution
was presented as a function of the volume of artiﬁcial urine
solution used. The mean ﬂuorescence values were normalized by
subtracting the background ﬂuorescence provided by the bladder
tissue prior to exposing it to the test material and the initial (pre-
wash) ﬂuorescence was taken as an intensity of 1.
Since the wash off experiments were not carried out in total
darkness, to exclude the possibility of the ﬂuorophore bleaching
with time, a portion of thiolated nanoparticles dispersion was
placed on the urinary bladder surface and ﬂuorescence measured
over 5 h. Fig. S1 shows that no signiﬁcant decrease (Anova, Tukey’s
multiple comparison’s test, p = 0.2247) in the ﬂuorescence
intensity of nanoparticle dispersion on the bladder surface was
observed over 5 h, indicating their suitability for this type of
analysis.
WO50 values, representing the volume of artiﬁcial urine
required to wash out 50% of the particles, were calculated from
the wash-off proﬁles. For example, WO50 values for chitosan and
dextran were calculated via extrapolation of the wash-off results to
50% using linear and exponential ﬁts, respectively.
3. Results and discussion
3.1. Synthesis and characterization of ﬂuorescently-labelled thiolated
and PEGylated silica nanoparticles
Thiolated silica nanoparticles were synthesized using self-
condensation of (3-mercaptopropyl)trimethoxysilane (MPTS) in
aprotic solvents in an oxidative environment (bubbling with air)
and with small portions of aqueous NaOH as a catalyst. Previously
(Mun et al., 2014b) we showed that the self-condensation of MPTS
in dimethylsulfoxide forms nanoparticles of 21 1 nm and
45 1 nm, when the concentration of MPTS in the feed mixturewas 0.1 mol/L and 0.2 mol/L, respectively. These two types of
nanoparticles were also synthesized in the present study.
Additionally, in this study we conducted the reaction in other
aprotic solvents, namely dimethylformamide (DMF) and acetoni-
trile (AcN) for nanoparticle synthesis. Maintaining the MPTS at
0.1 mol/L, nanoparticles of 95 14 and 217  7 nm were produced
in DMF and AcN, respectively. The effect of aprotic solvent nature
on the dimensions and properties of thiolated silica nanoparticles
has not been reported previously. By changing the concentration of
MPTS in the feed mixture and by changing the nature of aprotic
solvent it is possible to make the thiolated silica nanoparticles with
a range of different sizes. It is widely recognized (Plumere et al.,
2012) that formation of silica particles from alkoxysilanes (e.g.
tetraalkoxysilane) proceeds via several stages such as hydrolysis,
condensation, nucleation, aggregation and particle growth. The
growth of primary particles as well as their further aggregation are
dependent on thermodynamic parameters of the system control-
ling their colloidal stability. Polarity of the solvent is one of the
factors affecting the particles at the nucleation stage. Smaller
particles are expected to form in solvents of greater polarity (Wang
et al., 2006), which was observed in this work.
All nanoparticles were ﬂuorescently labelled by reacting with
5-(iodoacetamido)-ﬂuorescein (5-IAF). The ﬂuorophore was added
into the reaction mixture in a 5:50 mmol ratio with regards to the
number of SH-groups of silica nanoparticles; thus there were still
numerous thiol-groups available for mucoadhesion and for further
functionalization. The ﬂuorescently labelled nanoparticles were
characterized using dynamic light scattering, ﬂuorescent spec-
troscopy and Ellman’s assay. Fig. 1 shows size distributions of the
nanoparticles formed in DMSO, DMF and AcN, determined using
dynamic light scattering, illustrating the inﬂuence of changing
solvent polarity on particle size, but with similar dispersities.
Previously (Irmukhametova et al., 2011) it was demonstrated
that PEGylation prevents the adhesion of thiolated silica to intact
bovine cornea, but could facilitate their penetration into more
porous stroma in de-epithelialized cornea (Mun et al., 2014a,b).
Clearly, deeper penetration of particles into a biological tissue
could also improve their retention, which means that PEGylation
may have various effects on particle behavior on different mucosal
surfaces. In this work the effect of thiolated silica PEGylation was
studied in relation to urinary bladder mucosa.
A portion of ﬂuorescently-labelled thiolated nanoparticles
synthesized in DMSO (45 1 nm) was additionally reacted with
Table 1
Characteristics of ﬂuorescently-labelled thiolated and PEGylated silica nanoparticles.
Sample Diameter, nm PDI Nanoparticle concentration, mg/mL [SH], mmol/g WO50 a, mL
Thiolated (DMSO + 0.2 mol/L MPTS) 45  1 0.332 5 249  30 36
PEGylated (750 Da) 54  1 0.194 5 95  6 29
PEGylated (5000 Da) 69  2 0.145 7 78  5 8
Thiolated (DMSO + 0.1 mol/L MPTS) 21  1 0.263 4 118  14 17
Thiolated (DMF + 0.1 mol/L MPTS) 95  14 0.310 4 119  12 7
Thiolated (AcN+ 0.1 mol/L MPTS) 217  7 0.056 3 40  6 6
a WO50 is the volume of artiﬁcial urine required to wash out 50% of the particles.
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5000 Da) to generate two PEGylated silica nanoparticles. The
general characteristics of all silica nanoparticles synthesized in this
work are summarized in Table 1.
As expected, PEGylation generated larger nanoparticle size
distributions, similar to our previous ﬁndings (Mun et al., 2014b).
The sizes of thiolated and PEGylated nanoparticles were signiﬁ-
cantly different (ANOVA; Tukey’s multiple comparisons test;
p < 0.001) showing that the greater the molecular weight of PEG
shell, the larger the nanoparticles.
PEGylation also reduced thiol groups content from 249  30
mmol/g to 95  6 mmol/g and 78  5 mmol/g, when the nano-
particles were decorated with 750 Da and 5000 Da PEG, respec-
tively. Additionally, due to the screening effect of the PEG shells,
reduced ﬂuorescence intensity was observed for PEGylated nano-
particles. PEG of a larger molecular weight provided the lowest
ﬂuorescence intensity, since screening with PEG 5000 Da is greater
than with PEG 750 Da. For thiolated samples prepared in different
solvents, the lowest ﬂuorescence intensity was observed for those
synthesized in acetonitrile, which contained the lowest amount of
SH-groups on their surface and hence a lower quantity of the
ﬂuorophore conjugated.
3.2. Comparative mucoadhesion studies of thiolated and PEGylated
nanoparticles
Bernkop-Schnurch introduced thiolated polymers (thiomers)
as a new generation of mucoadhesive materials (Bernkop-
Schnurch, 2005). Thiomers exhibit enhanced mucoadhesion
compared to their unmodiﬁed parent polymers due to the
formation of disulﬁde bridges (covalent bonds) between thiol-
groups of the polymer and cysteine-rich domains of mucus
glycoproteins. Barthelmes et al. (2011) reported the synthesis of
chitosan-thioglycolic acid nanoparticles, loaded with trimetho-
prim, for targeted drug release in the urinary bladder. These
nanoparticles enabled controlled and sustainable drug release,
showed greater stability and superior mucoadhesion compared to
unmodiﬁed chitosan particles. The presence of thiol groups on the
surface of silica nanoparticles also makes them promising as
mucoadhesive materials for application in drug delivery.
The retention of ﬂuorescently-labelled thiolated and PEGylated
silica nanoparticles on porcine urinary bladder mucosa was
studied using a ﬂow-through method with ﬂuorescent detection
(Irmukhametova et al., 2011; Storha et al., 2013; Withers et al.,
2013). Fig. 2 shows representative ﬂuorescent images of the
retention of thiolated and PEGylated silica as well as two controls
(chitosan and dextran) on urinary bladder mucosa, washed with
artiﬁcial urine. Fluorescently-labelled chitosan was selected as a
positive control because it is a cationic polymer with well-
documented ability to adhere to mucosal surfaces (Sogias et al.,
2008; Khutoryanskiy, 2011). Fluorescently-labelled dextran, on the
contrary, had very poor adhesion to mucosal surfaces (Storha et al.,
2013; Withers et al., 2013), and so was used as a negative control in
our experiments.Analysis of the ﬂuorescent images using ImageJ software allows
the retention of ﬂuorescent species on mucosal surfaces to be
quantiﬁed (Fig. 3). FITC-chitosan is retained on the bladder surface
even after 7 washes (total volume 70 mL) with artiﬁcial urine
solution and illustrates its strong interaction with the mucosal
surface. However, for FITC-dextran, a signiﬁcant decrease in
ﬂuorescence was observed after the ﬁrst wash (10 mL) with urine
solution, conﬁrming its poor mucoadhesive properties.
Retention of thiolated silica nanoparticles on the bladder
mucosa was signiﬁcantly higher than for FITC-dextran (p < 0.05):
approximately 15% of the ﬂuorescence, hence particles, remains on
the mucosal surface even after 7 washing cycles with 10 mL of
artiﬁcial urine solution. However, their retention was signiﬁcantly
lower than FITC-chitosan (p < 0.05). This may be due to the
polymeric nature of chitosan, whose positively-charged macro-
molecules are able to penetrate into the mucosal layer of the
bladder epithelium, form non-covalent interactions (e.g. electro-
static attraction and hydrogen bonding) with mucins and generate
an interpenetration layer (Sogias et al., 2008). This interpenetra-
tion could potentially facilitate better retention of chitosan on the
bladder mucosa compared to thiolated nanoparticles.
PEGylated silica nanoparticles were washed from the mucosal
surface more rapidly than the thiolated parent particles and hence
are less mucoadhesive. The normalized ﬂuorescence intensity of
PEGylated (750 Da) nanoparticles on the bladder surface was
similar (T-test, p = 0.8937) to that of its thiolated counterpart after
the ﬁrst wash. Whilst the thiolated nanoparticles stayed on the
bladder surface after 7 washes, PEGylated (750 Da) nanoparticles
were completely removed after 6 washes. PEGylated (5000 Da)
nanoparticles revealed poorer retention than when modiﬁed with
750 Da PEG and were removed after 5 washes, similar to the
negative control, FITC-dextran. Weaker retention for the PEGylated
(5000 Da) silica relates to greater screening of the surface thiol
groups by the larger molecular weight polymer and to the thiol
content on the nanoparticle surface itself (Table 1).
The poorer mucoadhesive performance of PEGylated nano-
particles compared to the thiolated silica is in good agreement
with our previous study of retention of similar nanoparticles on the
ocular surfaces (Irmukhametova et al., 2011). However, both
thiolated and PEGylated (5000 Da) nanoparticles in our previous
report demonstrated a very sharp drop in ﬂuorescence intensity (of
62% and 95%, respectively) after the ﬁrst wash and the PEGylated
nanoparticles were removed from the ocular surface after three
washes. Here, PEGylated (PEG 5000 Da) nanoparticles were
removed from the bladder mucosa after 6 wash cycles. This
discrepancy can be explained by the different nature of two
mucosal tissues (Irmukhametova et al., 2011); the rougher
structure of the bladder epithelium compared to the cornea
provides better retention of silica nanoparticles on its mucosal
surface.
Retention studies were conducted with differing sizes of
thiolated silica nanoparticles, synthesized in different aprotic
solvents (DMSO, DMF and AcN, Table 1). Fig. 4 shows the retention
proﬁles for these nanoparticles.
Fig. 2. Exemplar ﬂuorescence microphotographs showing retention of FITC-chitosan, thiolated silica, PEGylated silica (750 Da), PEGylated silica (5000 Da) and FITC-dextran
on porcine urinary bladder mucosa as washed with different volumes of artiﬁcial urine solution. Scale bar is 200 mm.
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thiolated nanoparticles, synthesized in DMSO: they remain on the
surface of the bladder mucosa for up to 6–7 washes with 10 mL of
artiﬁcial urine. The nanoparticles synthesized in DMF are much
larger (95 14 nm), but have similar thiol content as the thiolatedFig. 3. Fluorescence intensities showing retention of FITC-chitosan, thiolated silica, PEGy
bladder mucosa after washing with different volumes of artiﬁcial urine solution. Each
value  standard deviation. Initial intensity after dosing is taken as a value of 1.silica prepared in DMSO (119  12 mmol/g and 118  14 mmol/g,
respectively). Their retention on the bladder mucosa is poorer and
no traces of these nanoparticles are detectable after 7 wash cycles.
This clearly indicates that the nanoparticles of larger size have
weaker retention on the bladder mucosa, which is possibly relatedlated silica (750 Da), PEGylated silica (5000 Da) and FITC-dextran on porcine urinary
 experiment was performed in triplicate and results are presented as the mean
Fig. 4. Fluorescence levels showing retention of thiolated silica nanoparticles synthesized in DMSO, DMF and AcN on the urinary bladder surface washed with artiﬁcial urine.
Each experiment was performed in triplicate and the results are presented as the mean value  standard deviation.
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weakest retention on the bladder mucosa was observed for the
thiolated silica synthesized in AcN. Both their large size
(217  7 nm) and low SH-groups content (40  6 mmol/g) could
contribute to this poor mucoadhesive performance.
A comparison between the nanoparticles synthesized in DMSO
from the feed mixtures containing different quantities of MPTS
reveals that the thiolated silica of 45 1 nm (Fig. 3) retains on the
bladder mucosa better than 21 1 nm nanoparticles (Fig. 4). This is
explained by the greater thiol content (249  30 mmol/g) of the
45 1 nm particles compared to 21 1 nm material which had a
lower concentration of SH-groups (118  14 mmol/g).
Direct quantitative comparisons between different wash-off
proﬁles is problematic unless each set of data could be converted
into a simple numerical value. To this end, we propose WO50
values, which represent the volume of a biological ﬂuid required to
wash out 50% of the mucoadhesive ingredient from a substrate
surface. These values were calculated by analyzing individual
wash-off proﬁles and the results are summarized in Table 1. By
comparing these values for different particles used in this study, it
is clear that the greatest retention is observed for 45 1 nm
thiolated silica particles with the highest SH-groups content
(249  30 mmol/g), whose WO50 is 36 mL. PEGylation of these
particles reduces their retention with WO50 values dropping to 29
and 8 mL for 750 Da and 5000 Da PEG, respectively. Thiolated
nanoparticles have greater retention on bladder mucosa compared
to non-mucoadhesive dextran (WO50 7 mL), but have weaker
mucoadhesive properties than chitosan (WO50 89 mL).
The smallest thiolated particles of 21 1 nm diameter have a
lower SH-groups content (118  14 mmol/g) than those of
45 1 nm diameter and showed an expectedly lower WO50 of
17 mL. However, the nanoparticles synthesized in DMF are larger
(95 14 nm), have a similar SH-groups content (119  12 mmol/g)
but are more readily washed from the tissue (WO50 7 mL). Hence
the retention of particles on mucosal surfaces is not only
dependent on their surface thiol-groups but also on their size.
Indeed, the largest thiolated particles synthesized in acetonitrile
(217  7 nm) have the lowest SH-groups content (40  6 mmol/g)
and exhibit weakest retention on mucosal surfaces (WO50 = 6 mL).
3.3. Conclusions
The retention of thiolated and PEGylated silica nanoparticles on
porcine urinary bladder mucosa has been studied in vitro usingﬂuorescence microscopy. It was shown that the thiolated nano-
particles adhere well to bladder mucosa and withstand wash out
effects caused by urine. Retention of these nanoparticles depends
on their thiol-content and dimensions. PEGylation of thiolated
silica greatly reduces their mucoadhesive properties. The use of
WO50 values, introduced in this work, provides a convenient
method to quantitatively compare the retention of particulates and
other materials on differing mucosal surfaces and between
differing research protocols.
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